Cost inputs
| Parameter | Cost (€) | Source |
| Active cancer treatment | ||
| Weighted average monthly cost of treatment | ||
| First-line | ||
| HER2−/HR+ | 1184 € | 13 15–20 |
| HER2+/HR+ | 7404 € | |
| HER2+/HR− | 7491 € | |
| Triple negative | 2823 € | |
| Second-line | ||
| HER2−/HR+ | 1670 € | 13 15–20 |
| HER2+/HR+ | 6869 € | |
| HER2+/HR− | 6656 € | |
| Triple negative | 1534 € | |
| Third-line | ||
| HER2−/HR+ | 1967 € | 13 15–20 |
| HER2+/HR+ | 6534 € | |
| HER2+/HR− | 6349 € | |
| Triple negative | 1609 € | |
| Treatment of bone metastases | ||
| Weighted average monthly cost of bone metastasis treatment | 316 € | 13 15–20 |
| Toxicity management | ||
| Per-event toxicity management cost | ||
| Neutropaenia | 546 € | 13 15–20 |
| Febrile neutropaenia | 1875 € | |
| Leucopaenia | 390 € | |
| Lymphopaenia | 79 € | |
| Thrombocytopaenia | 1295 € | |
| Infection | 993 € | |
| Anaemia | 1794 € | |
| Haemorrhage | 3233 € | |
| All neuropathies | 644 € | |
| Nausea | 362 € | |
| Vomiting | 592 € | |
| Diarrhoea | 931 € | |
| Dehydration | 955 € | |
| Pain | 1255 € | |
| Hypersensitivity | 366 € | |
| Stomatitis/mucositis | 968 € | |
| Alopecia | 95 € | |
| Hepatobiliary – alanine aminotransferase | 358 € | |
| Hepatobiliary – aspartate aminotransferase | 358 € | |
| Hyperbilirubinaemia | 602 € | |
| Increased alkaline phosphatase | 200 € | |
| Hypertension | 417 € | |
| Dyspnea | 1241 € | |
| Fatigue | 895 € | |
| Skin reaction | 241 € | |
| Fluid retention | 687 € | |
| Hand and foot syndrome | 270 € | |
| Asthaenia | 953 € | |
| Diagnosis | ||
| One-time cost of diagnosis | 1191 € | 13 15–20 |
| Medical follow-up during active treatment | ||
| Monthly cost of outpatient care during active treatment | 436 € | 13 15–20 |
| Monthly cost of hospitalisations during active treatment | 635 € | |
| Palliative/best supportive care | ||
| One-time cost of medications during palliative/best supportive care | 391 € | 13 15–20 |
| Monthly cost of medications during palliative/best supportive care | 2656 € | |
| Monthly cost of outpatient care during palliative/best supportive care | 330 € | |
| Monthly cost of hospitalisations during palliative/best supportive care | 1668 € | |
| Monthly cost of community/social services during palliative/best supportive care | 602 € | |
| Indirect costs | ||
| Monthly lost income | 8 € | 1 21 |
HER2, human epidermal growth factor receptor 2; HR, hormonal receptor.